Galecto Inc. (GLTO) NASDAQ

$1.29 0.07 (5.74%)

Market Cap: $32.59M

As of 05/25/22 04:00 PM EDT. Market closed.

(GLTO)

Galecto Inc. (GLTO) NASDAQ

$1.29 0.07 (5.74%)

Market Cap: $32.59M

As of 05/25/22 04:00 PM EDT. Market closed.

Galecto is a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets which are at the heart of fibrosis, inflammation, and cancer. Galecto was founded by leading fibrosis-focused scientists and biotech executives and is built on more than 10 years of research into galectin and fibrosis modulators. The Company's team has ... read more

Galecto is a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets which are at the heart of fibrosis, inflammation, and cancer. Galecto was founded by leading fibrosis-focused scientists and biotech executives and is built on more than 10 years of research into galectin and fibrosis modulators. The Company's team has developed a deep understanding of the galectin family of proteins and the LOXL2 enzyme, and how both influence multiple biological pathways of these complex, often devastating, diseases. read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
URL
Address
.
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
Full Time Employees
28
Address
.
PRICE CHART
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
KEY STATS
Open
$0
Previous Close
$1.22
Days Range
$1.27 - $1.31
52 week range
$1.17 - $16.41
Volume
71,839
Avg. Volume (30 days)
65,405
Market Cap
$32.59M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
25,261,832
Open
$0
Previous Close
$1.22
Days Range
$1.27 - $1.31
52 week range
$1.17 - $16.41
Volume
71,839
Avg. Volume (30 days)
65,405
Market Cap
$32.59M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
25,261,832

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR GALECTO INC
Owner Relationship Date Transaction Cost # Shares Value($) Total Shares Form 4
Lindmark Bertil Chief Medical Officer Mar 22, 2022 Buy $2.16 14,604 31,545 16,604 Mar 23, 2022, 08:00 AM
Schambye Hans T. Chief Executive Officer Mar 22, 2022 Buy $2.15 5,000 10,750 52,428 Mar 23, 2022, 08:00 AM
Winslow Garrett General Counsel Dec 03, 2021 Buy $2.48 2,000 4,960 4,000 Dec 06, 2021, 08:00 AM
Freve Jonathan Chief Financial Officer Dec 03, 2021 Buy $2.49 4,000 9,960 12,000 Dec 06, 2021, 08:00 AM
Schambye Hans T. Chief Executive Officer Nov 09, 2021 Buy $3.50 4,500 15,750 47,428 Nov 10, 2021, 08:00 AM
Freve Jonathan Chief Financial Officer Nov 08, 2021 Buy $3.40 3,000 10,200 8,000 Nov 09, 2021, 08:00 AM
Freve Jonathan Chief Financial Officer Aug 18, 2021 Buy $3.92 3,000 11,760 5,000 Aug 19, 2021, 04:00 PM
Lindmark Bertil Chief Medical Officer Jun 28, 2021 Buy $5.26 2,000 10,520 2,000 Jun 28, 2021, 04:00 PM
Schambye Hans T. Chief Executive Officer Jun 24, 2021 Buy $5.11 3,000 15,330 42,928 Jun 24, 2021, 04:00 PM
Freve Jonathan Chief Financial Officer Jun 23, 2021 Buy $4.74 2,000 9,480 2,000 Jun 23, 2021, 04:00 PM
Winslow Garrett General Counsel Jun 23, 2021 Buy $4.80 2,000 9,600 2,000 Jun 23, 2021, 04:00 PM
ORBIMED ADVISORS LLC Director Nov 02, 2020 Buy $15.00 733,333 10,999,995 2,579,657 Nov 04, 2020, 08:00 PM
Khuong Chau Quang Director Nov 02, 2020 Buy $15.00 733,333 10,999,995 2,579,657 Nov 04, 2020, 08:00 PM
Christgau Stephan Director Nov 02, 2020 Buy $15.00 66,666 999,990 546,136 Nov 04, 2020, 08:00 PM
Novo Holdings A/S 10% Owner Nov 02, 2020 Buy $15.00 333,333 4,999,995 2,497,791 Nov 04, 2020, 07:52 PM
Load More Insider Transactions
Buy Sale Option Exercise
Owner Relationship Date Value($)
Lindmark Bertil Chief Medical Officer 03/22/2022 31,545
Schambye Hans T. Chief Executive Officer 03/22/2022 10,750
Winslow Garrett General Counsel 12/03/2021 4,960
Freve Jonathan Chief Financial Officer 12/03/2021 9,960
Schambye Hans T. Chief Executive Officer 11/09/2021 15,750
Freve Jonathan Chief Financial Officer 11/08/2021 10,200
Freve Jonathan Chief Financial Officer 08/18/2021 11,760
Lindmark Bertil Chief Medical Officer 06/28/2021 10,520
Schambye Hans T. Chief Executive Officer 06/24/2021 15,330
Freve Jonathan Chief Financial Officer 06/23/2021 9,480
Winslow Garrett General Counsel 06/23/2021 9,600
ORBIMED ADVISORS LLC Director 11/02/2020 10,999,995
Khuong Chau Quang Director 11/02/2020 10,999,995
Christgau Stephan Director 11/02/2020 999,990
Novo Holdings A/S 10% Owner 11/02/2020 4,999,995
Load More Insider Transactions
CHANGE IN SHARES OUTSTANDING
STOCK BUYBACKS
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
03/31/2022
12/31/2021
0%
1Q
03/31/2022
09/30/2021
0%
2Q
03/31/2022
06/30/2021
0%
3Q
03/31/2022
03/31/2021
0%
4Q
Load More

Period of Report: 03/31/2022

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
12/31/2021
0%
1Q
09/30/2021
0%
2Q
06/30/2021
0%
3Q
03/31/2021
0%
4Q
Load More